Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4792319 | 0.76 | NQO2 (0.48) | GAALMNAHPGDALDH1A1KDM4E | |
| SCHEMBL4770176 | 0.75 | GAA (0.47) | GAALMNAHPGDALDH1A1KDM4E | |
| SCHEMBL30531213 | 0.75 | SMN1; SMN2 (0.73) | GAALMNAHPGDALDH1A1KDM4E | |
| SCHEMBL28596962 | 0.75 | SMN1; SMN2 (0.73) | GAALMNAHPGDALDH1A1KDM4E | |
| SCHEMBL4174949 | 0.74 | SMN1; SMN2 (0.58) | GAALMNAHPGDALDH1A1KDM4E | |
| SCHEMBL3972158 | 0.72 | ALDH1A1 (0.45) | HPGDALDH1A1KDM4ESMN1; SMN2CYP2C9 | |
| SCHEMBL12021198 | 0.72 | ALDH1A1 (0.43) | GAALMNAHPGDALDH1A1KDM4E | |
| SCHEMBL14666358 | 0.70 | CFTR (0.53) | GAALMNAHPGDALDH1A1KDM4E | |
| SCHEMBL15903170 | 0.70 | CFTR (0.53) | GAALMNAHPGDALDH1A1KDM4E | |
| SCHEMBL28354652 | 0.70 | SMN1; SMN2 (0.47) | HPGDALDH1A1KDM4ESMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393851-B2 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393851-B2 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393851-B2 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1560582-A4 | AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE | SCIOS INC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1560582-A2 | AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE | SCIOS INC. (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20040176598-A1 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS, INC. | 2004-09-09 | — | — | US | disclosed |
| WO-2004032874-A2 | AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE | SCIOS INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176598-A1 | Azaindole derivatives as inhibitors of p38 kinase | MAPKAPK2, MAPK1, MAPK4 | GAA 4654/4885LMNA 3671/4885HPGD 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.